Molex to Acquire Vectura Group, Enhancing Inhalation Drug Delivery Capabilities
Hudson, WI – September 17, 2024 – Molex, the parent company of Phillips Medisize, announced today that it has signed an agreement to acquire Vectura Group Limited, a leader in inhalation drug device design and formulation. The acquisition, facilitated through Molex Asia Holdings LTD., will expand Phillips Medisize's capabilities in drug delivery and solidify its position in the pharmaceutical sector.
Vectura, based in Chippenham, United Kingdom, is recognized for its innovative solutions in inhalation therapies, including dry powder inhalers (DPI), pressurized metered dose inhalers (pMDI), and nebulizer products. With this acquisition, Phillips Medisize aims to leverage Vectura's expertise in formulation and device development to enhance its portfolio of inhalation combination drug devices.
“Combining the strengths of Phillips Medisize and Vectura will enhance our ability to deliver a broader portfolio of inhalation combination drug devices and solutions to our pharmaceutical customers,” stated Paul Chaffin, President of Phillips Medisize. “With our global reach, manufacturing scale, and engineering expertise, we are uniquely positioned to help Vectura develop innovative new products that will benefit patients suffering from chronic and acute diseases such as asthma and COPD.”
In addition to its device development capabilities, Vectura offers a comprehensive range of services, including pharmaceutical analysis, process development, technical transfer, and clinical trial supplies. This acquisition will enable Phillips Medisize to better serve its customers and expand its market-leading position in the inhalation drug delivery space.
The acquisition reflects Molex's commitment to enhancing its healthcare offerings. “The acquisition of Vectura is the latest step in building an industry-leading capability in medical,” said Joe Nelligan, CEO of Molex. “We are excited about the significant growth potential that comes with a wider range of formulation, device design, combination product development, and manufacturing services to support the increasing need for inhalation therapies.”
The deal is expected to close by the end of 2024, pending regulatory approvals and other customary conditions. Vectura employees will become part of a larger global organization dedicated to improving patient outcomes through innovative products and world-class manufacturing capabilities.